Nkarta Inc
NKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$197.47M
Close$
$-0.50
117.8% downside
Current Fair Value
117.8% downsideOvervalued by 117.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $197.47 Million |
|---|---|
| Enterprise Value | $246.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 0.94 |
| Outstanding Shares | 74,494,855 |
Return
| Return on Equity | -47.36% |
|---|---|
| Return on Assets | -34.75% |
| Return on Invested Capital | -39.45% |
Valuation & Multiples
| P/E Ratio | -1.76 |
|---|---|
| PEG | -2.32 |
| Price to Sales | - |
| Price to Book Ratio | 0.93 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.99 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5379▲ 53.79% |
|---|---|
| Total Calls | 68,600▲ Infinity% |
| Total Puts | 36,900▼ 55.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 77.70%▲ 2.36% |
|---|---|
| Total Invested | $121.64M▲ 17.92% |
| Investors Holding | 130▲ 9.00% |
ESG Score
No data
About Nkarta Inc
95 employeesNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell en...